fbpx
February 1, 2021

Potassium Iodide Tablets – Shelf Life Extension

Docket Number: FDA-2003-D-0029 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research This document is intended to provide guidance to Federal agencies and to […]
February 1, 2021

Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices

Docket Number: FDA-2011-D-0868 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research Center for Biologics Evaluation and Research Center for Devices and Radiological Health […]
February 1, 2021

Reports on the Status of Postmarketing Study Commitments — Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997

Docket Number: FDA-1999-N-0098 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research Center for Biologics Evaluation and Research The purpose of this guidance is […]
February 1, 2021

Reference Guide for the Nonclinical Toxicity Studies of Antivial Drugs Indicated for the Treatment of N/A Non-Life Threatening Disease Evaluation of Drug Toxicity Prior to Phase I Clinical Studies

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 – Specific Electronic Submissions Intended For FDA’s Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed […]
February 1, 2021

(Potassium Iodide) KI in Radiation Emergencies-Questions and Answers

Docket Number: None found Issued by: Guidance Issuing Office Center for Drug Evaluation and Research This guidance provides answers to questions that FDA has received as […]
February 1, 2021

Abuse-Deterrent Opioids-Evaluation and Labeling

Docket Number: FDA-2013-D-0045 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research This guidance explains FDA’s current thinking about the studies that should be […]
February 1, 2021

Carcinogenicity Study Protocol Submissions

Docket Number: FDA-2000-D-1405 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research This guidance is intended to inform sponsors of the types of information […]
February 1, 2021

Role of HIV Drug Resistance Testing in Antiretroviral Drug Development

Docket Number: FDA-2004-D-0242 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research This guidance is intended to assist sponsors in the clinical development of […]
February 1, 2021

Influenza: Developing Drugs for Treatment and/or Prophylaxis

Docket Number: FDA-2009-D-0044 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research The purpose of this guidance is to assist sponsors in the development […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0